Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Monlunabant
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Novo Nordisk
Deal Size : $1,075.0 million
Deal Type : Acquisition
Details : Through the acquisition, Inversago will further strengthen Nordisk's clinical pipeline in obesity, diabetes and other metabolic diseases by including its lead development asset INV-202, an oral CB1 inverse agonist, currently in a phase 2 trial for diabet...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $1,075.0 million
October 08, 2023
Lead Product(s) : Monlunabant
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Novo Nordisk
Deal Size : $1,075.0 million
Deal Type : Acquisition
Lead Product(s) : INV-202
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 07, 2023
Lead Product(s) : INV-202
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Monlunabant
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : INV-202 is a small molecule CB1 inverse agonist being developed by Inversago for the potential treatment of a range of cardiometabolic and fibrotic conditions, including diabetic kidney disease.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 29, 2022
Lead Product(s) : Monlunabant
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Monlunabant
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : New Enterprise Associates
Deal Size : $95.0 million
Deal Type : Series C Financing
Inversago Pharma Raises $95 million CAD in Series C Financing
Details : Proceeds from financing will be used to move lead program, INV-202, into a Phase 2 in Diabetic Kidney Disease in Q4 2022. Additionally, the funds will accelerate other programs currently in pre-clinical development, while establishing its leadership in C...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
October 17, 2022
Lead Product(s) : Monlunabant
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : New Enterprise Associates
Deal Size : $95.0 million
Deal Type : Series C Financing
Lead Product(s) : Monlunabant
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Inversago Pharma Receives IND Clearance for Phase 2 Trial of INV-202 in Diabetic Kidney Disease
Details : INV-202 showed a favorable profile in a first-in-human study, including safety and tolerability, oral absorption, and pharmacokinetics. It also demonstrated potential for decreased appetite, a relevant pharmacodynamic marker of early efficacy of Inversag...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 15, 2022
Lead Product(s) : Monlunabant
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : INV-202
Therapeutic Area : Nephrology
Study Phase : Phase II
Sponsor : Worldwide Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2022
Lead Product(s) : INV-202
Therapeutic Area : Nephrology
Highest Development Status : Phase II
Sponsor : Worldwide Clinical Trials
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Monlunabant
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Inversago Pharma Presents Data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress
Details : INV-202 is a small molecule CB1 inverse agonist / antagonist being developed by Inversago for the potential treatment of several metabolic conditions, including Diabetic Nephropathy.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 19, 2022
Lead Product(s) : Monlunabant
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : INV-202
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Explore the PK and PD of INV-202 in Metabolic Syndrome
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 16, 2022
Lead Product(s) : INV-202
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Monlunabant
Therapeutic Area : Nephrology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : INV-202, first-in-class, peripheral CB1 inhibitor, demonstrated efficacy in addressing multiple pathways involved in renal injury also have shown clinical improvements in lipids, weight loss and glucose.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 15, 2022
Lead Product(s) : Monlunabant
Therapeutic Area : Nephrology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Monlunabant
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : As a new generation peripheral CB1 inverse agonist / antagonist, INV-202 has the potential to treat various metabolic conditions such as Prader-Willi syndrome (PWS), NASH, type 1 diabetes (T1D), diabetic nephropathy and chronic kidney diseases, among oth...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 09, 2021
Lead Product(s) : Monlunabant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable